Licensing status

Publication and contact information



Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Cell culture and mouse studies have identified a small molecule inducer of TRAIL expression that could help treat cancer. A cell-based screen identified a compound, TRAIL-inducing compound 10 (TIC10), that upregulated TRAIL expression at low micromolar concentrations and induced apoptosis in a panel of cancer cell lines. In multiple mouse xenograft models of cancer, TIC10 decreased tumor growth and increased survival compared with vehicle control. Next steps include an IND filing at Oncoceutics Inc., for which the corresponding author is founder and CSO (see Making TRAIL, page 4).

SciBX 6(8); doi:10.1038/scibx.2013.190
Published online Feb. 28, 2013

Patent application filed; exclusively licensed to Oncoceutics

Allen, J.E. et al. Sci. Transl. Med.; published online Feb. 6, 2013;
Contact: Wafik S. El-Deiry, Penn State Milton S. Hershey Medical Center, Hershey, Pa.